This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-13. Anything still debated is marked as such rather than presented as settled.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Chemical Formula: C24H44O6 HLB Value: 4.3; suitable for water-in-oil (W/O) emulsions. Soluble in warm water and has good dispersibility in organic solvents such as ethanol and ethyl acetate. Physical Form: Amber liquid Fatty acid composition: Oleic acid (C18:1) ≤ 60%; balance primarily linoleic (C18:2), linolenic (C18:3) and palmitic (C16:0) acids. At high concentrations, sorbitan monooleate can increase the viscosity of the emulsion, which can further enhance stability by reducing the movement of dispersed droplets. When combined with other surfactants, especially those with higher HLB values like Tween 80, sorbitan monooleate can contribute to the overall stability of oil-in-water (O/W) emulsions. This combination allows for the creation of emulsifying systems with various HLB values, enabling the emulsification of a wide range of oils and waxes.
=== Expansion === SHIELD Illinois was originally intended to be a facilitator, assisting laboratories in preparing to use the covidSHIELD assay and advising colleges, universities, and other organizations on how to collect specimens. SHIELD Illinois would also provide the technology needed to transmit orders to the lab and results back to the collecting agency. It was estimated that the program would have 50 testing locations and collect 1.5 million tests over a six-month period. Over time, SHIELD Illinois's role expanded beyond its original advisory function, and it became involved in the logistics of running both laboratories and collection sites. However, the estimated number of labs and locations remained the same. This changed in March 2021, when the University of Illinois System entered into an Intergovernmental Agreement with the Illinois Department of Public Health to offer testing to every school district, community college, and public university in Illinois, as well as community testing sites for the general public throughout the state. There are 853 school districts covering 3,977 with 1.9 million students in Illinois. As of October 2022, the company had performed over 6.5 million tests at over 1,700 sites in Illinois, including the governor's office, the state legislature, and the United States District Court for the Northern District of Illinois; engaged 12 CLIA or CAP-certified laboratories; and built a transportation network covering 80,000 square miles.
During translation, ribosomes synthesize polypeptide chains from mRNA template molecules. In eukaryotes, translation occurs in the cytoplasm of the cell, where the ribosomes are located either free floating or attached to the rough endoplasmic reticulum. In prokaryotes, which lack a nucleus, the processes of both transcription and translation occur in the cytoplasm. Ribosomes are complex molecular machines, made of a mixture of protein and ribosomal RNA, arranged into two subunits (a large and a small subunit), which surround the mRNA molecule. The ribosome reads the mRNA molecule in a 5'-3' direction and uses it as a template to determine the order of amino acids in the polypeptide chain. To translate the mRNA molecule, the ribosome uses small molecules, known as transfer RNAs (tRNA), to deliver the correct amino acids to the ribosome. Each tRNA is composed of 70–80 nucleotides and adopts a characteristic cloverleaf structure due to the formation of hydrogen bonds between the nucleotides within the molecule. There are around 60 different types of tRNAs, each tRNA binds to a specific sequence of three nucleotides (triplets known as codons) within the mRNA molecule and delivers a specific amino acid. The ribosome initially attaches to the mRNA at the start codon (AUG) and begins to translate the molecule. The mRNA nucleotide sequence is read in codons (three adjacent nucleotides in the mRNA molecule correspond to a single codon).
Sources: en.wikipedia.org
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, it is listed on the Bombay Stock Exchange and the National Stock Exchange of India. The company produces and distributes medicines in more than 80 countries, with operations concentrated in India, North America, Europe, and emerging markets. As of March 2026, it employed approximately 17,000 people. Its name derives from Saldanha's sons, Glenn and Mark.
== Side effects == Progesterone is well tolerated, and many clinical studies have reported no side effects. Side effects of progesterone may include abdominal cramps, back pain, breast tenderness, constipation, nausea, dizziness, edema, vaginal bleeding, hypotension, fatigue, dysphoria, depression, and irritability, among others. Central nervous system depression, such as sedation and cognitive/memory impairment, can also occur. Vaginal progesterone may be associated with vaginal irritation, itchiness, and discharge, decreased libido, painful sexual intercourse, vaginal bleeding or spotting in association with cramps, and local warmth or a "feeling of coolness" without discharge. Intramuscular injection may cause mild-to-moderate pain at the site of injection. High intramuscular doses of progesterone have been associated with increased body temperature, which may be alleviated with paracetamol treatment. Progesterone lacks undesirable off-target hormonal activity, in contrast to various progestins. As a result, it is not associated with androgenic, antiandrogenic, estrogenic, or glucocorticoid effects. Conversely, progesterone can still produce side effects related to its antimineralocorticoid and neurosteroid activity. Compared to the progestin medroxyprogesterone acetate, there are fewer reports of breast tenderness with progesterone. In addition, the magnitude and duration of vaginal bleeding with progesterone are reported to be lower than with medroxyprogesterone acetate.
== Sources == Bushkovitch, Paul (5 December 2011). A Concise History of Russia. Cambridge University Press. ISBN 978-1-139-50444-7. Crummey, Robert O. (6 June 2014). The Formation of Muscovy 1300 - 1613. Routledge. ISBN 978-1-317-87200-9. Fennell, John (15 November 2023). The Emergence of Moscow, 1304–1359. Univ of California Press. ISBN 978-0-520-34759-5. Kuchkin, Vladimir A. (2013). "Московское великое княжество" [Grand Principality of Moscow]. In Kravets, S. L. (ed.). Большая российская энциклопедия. Том 21: Монголы — Наноматериалы (in Russian). Большая российская энциклопедия. pp. 308–310. ISBN 978-5-85270-355-2. Archived from the original on 20 May 2026. Riasanovsky, Nicholas V.; Steinberg, Mark D. (2019). A history of Russia (Ninth ed.). New York: Oxford University Press. ISBN 978-0-19-064558-8. Smirnova, E. S. (2013). "Московская школа" [Moscow school]. In Kravets, S. L. (ed.). Большая Российская энциклопедия. Том 21: Монголы — Наноматериалы (in Russian). Большая Российская энциклопедия. pp. 273–274. ISBN 978-5-85270-355-2.
In 1971, New York Times reporter James Reston published an article on his acupuncture experiences in China, which led to more investigation of and support for acupuncture. The US President Richard Nixon visited China in 1972. During one part of the visit, the delegation was shown a patient undergoing major surgery while fully awake, ostensibly receiving acupuncture rather than anesthesia. Later it was found that the patients selected for the surgery had both a high pain tolerance and received heavy indoctrination before the operation; these demonstration cases were also frequently receiving morphine surreptitiously through an intravenous drip that observers were told contained only fluids and nutrients. One patient receiving open heart surgery while awake was ultimately found to have received a combination of three powerful sedatives as well as large injections of a local anesthetic into the wound. After the National Institute of Health expressed support for acupuncture for a limited number of conditions, adoption in the US grew further. In 1972 the first legal acupuncture center in the US was established in Washington DC and in 1973 the American Internal Revenue Service allowed acupuncture to be deducted as a medical expense. Ronald Reagan, as the governor of California, vetoed a law which decriminalized acupuncture. In 2006, a BBC documentary Alternative Medicine filmed a patient undergoing open heart surgery allegedly under acupuncture-induced anesthesia. It was later revealed that the patient had been given a cocktail of anesthetics.
Sources: en.wikipedia.org
==== Economic impact in the region ==== The practice of money laundering, among other economic and financial crimes seeps into the economic and political structures of most developing countries therefore resulting to political instability and economic digression. Money laundering is still a great concern for the financial services industry. About 50% of the money laundering incidents in Latin America were reported by organizations in the financial sector. According to PwC's 2014 global economic crime survey, in Latin America only 2.8% of respondents in Latin America claimed suffering Antitrust/Competition Law incidents, compared to 5.2% of respondents globally. It has been shown that money laundering has an impact on the financial behavior and macroeconomic performance of the industrialized countries. In these countries the macroeconomic consequences of money laundering are transmitted through several channels. Thus, money laundering complicates the formulation of economic policies. It is assumed that the proceeds of criminal activities are laundered by means of the notes and coins in circulation of the monetary substitutes. The laundering causes disproportionate changes in the relative prices of assets which implies that resources are allocated inefficiently; and, therefore may have negative implications for economic growth, apparently money laundering is associated with a lower economic growth.
=== Ephedrine supplement ban === In response to renewed calls for the regulation of ephedra, the U.S. Department of Health and Human Services commissioned a large meta-analysis of ephedra's safety and efficacy by the RAND Corporation. This study found that ephedra promoted modest short-term weight loss, but there was insufficient data to determine whether it was effective for long-term weight loss or performance enhancement. The use of ephedrine alkaloids in this study was associated with significant gastrointestinal, psychiatric, and autonomic side effects. Almost simultaneously, a study in Annals of Internal Medicine found that ephedrine alkaloids were 100 to 700 times more likely to cause a significant adverse reaction than other commonly used supplements such as kava or Ginkgo biloba. On December 30, 2003, the FDA issued a press release recommending that consumers stop buying and using products containing ephedrine alkaloids, and indicating its intention to ban the sale of ephedrine alkaloid-containing supplements. Subsequently, on April 12, 2004, the FDA issued a final rule banning the sale of ephedrine alkaloid-containing dietary supplements. Tommy Thompson, the Secretary of Health and Human Services, stated that "...These products pose unacceptable health risks, and any consumers who are still using them should stop immediately." Products containing ephedra extract remain legal to this day.
People with myasthenia gravis undergoing surgery with inhaled anesthetics (i.e., halothane, isoflurane, enflurane, and sevoflurane) may develop neuromuscular blockage and have an increased incidence of developing a life-threatening myasthenia crisis which must be treated by prolonged mechanical ventilation. In a study of 795 people with myasthenia gravis undergoing surgical removal of their thymus under general anesthesia, sugammadex, a neuromuscular-blocking drug (i.e., a drug that reverses neuromuscular blockade) significantly reduced the development of this crisis. Glucocorticoids: Glucocorticoids are anti-inflammatory agents that in initial studies were used at high dosages and found to worsen myasthenia gravis in 25-75% of cases. However, further studies found that glucocorticoids do have favorable effects on myasthenia gravis when taken long term. Two glucocorticoids, oral prednisone and prednisolone, are the first-line immunosuppressive treatment for myasthenia gravis. A review published in 2020 on 27 earlier publications found that myasthenia gravis was worsened by glucocorticoids in 33.3% of patients. These myasthenia gravis exacerbations seemed significantly greater for cortisone, intermediate for prednisone, and lowest for methylprednisolone. High dosages or alternate day dosages of prednisone were associated with exacerbation more frequently than low-dose treatments.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.